Identifies possible synergistic drug classes of your lead compound
Flexibility in number of anti-cancer reference agents and cell lines
Visualization of synergy by curve shift (IC50)
Reproducibility of synergistic hits is covered by independent repeat experiments before finalization of the study.
SynergyScreen™ is a large combinatorial screen in which your compound will be screened against a panel of 42 representative agents. The 42 anti-cancer agents each represent a group of compounds acting on the same target or by a similar molecular mechanism. Your compound will be added as a fixed dose to the full dose-response curve of the reference agent. The dose-response curve of the reference agent alone will be taken along as well. Synergy will be determined via curve-shift analysis. When an IC50 shift larger than 2 is observed, an independent repeat experiment will be performed to confirm the synergistic hit.
Anti-cancer reference library
More than 190 anti-cancer reference agents have been profiled on the Oncolines® cancer cell line panel. Pre-profiled anti-cancer drugs include standards of care but also clinical stage candidates and experimental therapeutics. IC50 profiles of the anti-cancer reference agents are compared and the correlation is visualized in the clustering wheel. Based on the clustering, drug classes with a similar mechanism of action can be identified. Oncolines has selected 42 anti-cancer agents representing the different drug classes to be used in the SynergyScreen™. This selection is flexible: reference agents can easily be added or swapped. Oncolines is happy to assist you in selecting suitable reference agents for your study.
Clustering wheel showing the hierarchical clustering of all compounds that have been profiled on the Oncolines® panel. Red dots indicates that compound is selected as one of the 42 representatives included in the SynergyScreen™.
For more information about SynergyScreen™, please contact us